177 related articles for article (PubMed ID: 31494468)
1. Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.
Teodori E; Contino M; Riganti C; Bartolucci G; Braconi L; Manetti D; Romanelli MN; Trezza A; Athanasios A; Spiga O; Perrone MG; Giampietro R; Gazzano E; Salerno M; Colabufo NA; Dei S
Eur J Med Chem; 2019 Nov; 182():111655. PubMed ID: 31494468
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.
Dei S; Coronnello M; Floriddia E; Bartolucci G; Bellucci C; Guandalini L; Manetti D; Romanelli MN; Salerno M; Bello I; Mini E; Teodori E
Eur J Med Chem; 2014 Nov; 87():398-412. PubMed ID: 25282263
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR).
Dei S; Romanelli MN; Manetti D; Chiaramonte N; Coronnello M; Salerno M; Teodori E
Bioorg Med Chem; 2018 Jan; 26(1):50-64. PubMed ID: 29162309
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
[TBL] [Abstract][Full Text] [Related]
6. N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.
Teodori E; Dei S; Coronnello M; Floriddia E; Bartolucci G; Manetti D; Romanelli MN; Santo Domingo Porqueras D; Salerno M
Eur J Med Chem; 2017 Feb; 127():586-598. PubMed ID: 28113128
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.
Martelli C; Coronnello M; Dei S; Manetti D; Orlandi F; Scapecchi S; Novella Romanelli M; Salerno M; Mini E; Teodori E
J Med Chem; 2010 Feb; 53(4):1755-62. PubMed ID: 20104851
[TBL] [Abstract][Full Text] [Related]
8. New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).
Orlandi F; Coronnello M; Bellucci C; Dei S; Guandalini L; Manetti D; Martelli C; Romanelli MN; Scapecchi S; Salerno M; Menif H; Bello I; Mini E; Teodori E
Bioorg Med Chem; 2013 Jan; 21(2):456-65. PubMed ID: 23245571
[TBL] [Abstract][Full Text] [Related]
9. 6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers.
Braconi L; Bartolucci G; Contino M; Chiaramonte N; Giampietro R; Manetti D; Perrone MG; Romanelli MN; Colabufo NA; Riganti C; Dei S; Teodori E
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):974-992. PubMed ID: 32253945
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in silico analysis of the vascular effects of asymmetrical N,N-bis(alkanol)amine aryl esters, novel multidrug resistance-reverting agents.
Fusi F; Durante M; Spiga O; Trezza A; Frosini M; Floriddia E; Teodori E; Dei S; Saponara S
Naunyn Schmiedebergs Arch Pharmacol; 2016 Sep; 389(9):1033-43. PubMed ID: 27351883
[TBL] [Abstract][Full Text] [Related]
11. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
[TBL] [Abstract][Full Text] [Related]
12. Monoterpene indole alkaloid azine derivatives as MDR reversal agents.
Paterna A; Khonkarn R; Mulhovo S; Moreno A; Madeira Girio P; Baubichon-Cortay H; Falson P; Ferreira MU
Bioorg Med Chem; 2018 Jan; 26(2):421-434. PubMed ID: 29233614
[TBL] [Abstract][Full Text] [Related]
13. Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
Teodori E; Braconi L; Bua S; Lapucci A; Bartolucci G; Manetti D; Romanelli MN; Dei S; Supuran CT; Coronnello M
Molecules; 2020 Apr; 25(7):. PubMed ID: 32290281
[TBL] [Abstract][Full Text] [Related]
14. Structure-Activity Relationship Studies on 6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Multidrug Resistance Reversers.
Teodori E; Dei S; Bartolucci G; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
ChemMedChem; 2017 Aug; 12(16):1369-1379. PubMed ID: 28570027
[TBL] [Abstract][Full Text] [Related]
15. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
16. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
17. Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
Biochim Biophys Acta Biomembr; 2017 Jan; 1859(1):69-79. PubMed ID: 27810353
[TBL] [Abstract][Full Text] [Related]
18. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
19. 1,2,3,4-Tetrahydroisoquinoline/2H-chromen-2-one conjugates as nanomolar P-glycoprotein inhibitors: Molecular determinants for affinity and selectivity over multidrug resistance associated protein 1.
Rullo M; Niso M; Pisani L; Carrieri A; Colabufo NA; Cellamare S; Altomare CD
Eur J Med Chem; 2019 Jan; 161():433-444. PubMed ID: 30384046
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Multidrug Resistance (MDR): Design, Biological Evaluation and Molecular Modelling Studies of 2,4-Substituted Quinazoline Derivatives.
Braconi L; Teodori E; Contino M; Riganti C; Bartolucci G; Manetti D; Romanelli MN; Perrone MG; Colabufo NA; Guglielmo S; Dei S
ChemMedChem; 2022 Jun; 17(12):e202200027. PubMed ID: 35416421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]